Dublin Medtech Zendra Health Targets €20 Million in Revenue by 2029
Zendra Health, a Dublin-based medical technology company, expects its revenue to reach €2.2 million in 2027 and €20 million by 2029, according to figures reported by the Business Post. Founded in 2017 by twin brothers Thomas and David Coleman, the Kill O’The Grange firm develops software platforms designed to streamline access to attention deficit hyperactivity disorder (ADHD) and autism treatment. The business employs a staff of seven and generated €250,000 in revenue last year.
UK Neurodevelopmental Assessment Waitlists Reach 800,000 People
Health services across multiple jurisdictions face severe backlogs in neurodevelopmental assessments, creating extensive waiting periods for patients. Approximately 800,000 people currently sit on waitlists in the UK, where children can wait up to four years and adults up to 18 years for an assessment, Thomas Coleman told the Business Post. Beyond initial diagnostic delays, patients and clinicians frequently encounter complex administrative hurdles.
Once assessments conclude, the resulting information is often poor in quality, making it difficult for clinicians to determine if medications are properly optimized or to effectively monitor physical health, according to Zendra Health. The company’s platform aims to reduce this administrative load by connecting parents, teachers, and clinicians into a single, centralized, evidence-based portal that functions as a continuous touchpoint throughout the patient journey.
Expansion Across Public and Private Healthcare Providers
Prior to establishing Zendra Health, Thomas Coleman worked as a software architect while David Coleman operated as an engineer. The brothers initially launched two products focusing on digitalizing patient journeys and care coordination in community health settings. After securing a contract for ADHD services, the founders recognized the operational complexity of the sector and directed their technology toward neurodivergent care pathways.
Following two years of research and development, the platform went live last year. The product is currently deployed across public and private healthcare providers in Ireland, integrated into two National Health Service (NHS) services in the UK, and has its first US use-case study in development, Thomas Coleman told the Business Post.
Collaboration with Trinity College Dublin and Enterprise Ireland
Enterprise Ireland supports the firm through feasibility grants, event signposting, and market advisors who assist with international market entry in the UK and United States. Zendra Health is currently collaborating with Trinity College Dublin to conduct further research. The company plans to expand its presence within the NHS to prepare for a broader market entry into the US scheduled for late 2027 or early 2028.
Related reading